Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Y Yang, S Li, Y Wang, Y Zhao, Q Li - Signal transduction and targeted …, 2022 - nature.com
Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
K Shi, G Wang, J Pei, J Zhang, J Wang… - Journal of Hematology & …, 2022 - Springer
Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth
factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related …
factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related …
Targeted therapy for cancers: from ongoing clinical trials to FDA-approved drugs
HY Choi, JE Chang - International Journal of Molecular Sciences, 2023 - mdpi.com
The development of targeted therapies has revolutionized cancer treatment, offering
improved efficacy with reduced side effects compared with traditional chemotherapy. This …
improved efficacy with reduced side effects compared with traditional chemotherapy. This …
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and …
YI Zhao, J Liu, X Cai, Z Pan, J Liu, W Yin, H Chen, Z Xie… - Bmj, 2019 - bmj.com
Objective To compare the efficacy and safety of first line treatments for patients with
advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer …
advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer …
Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma
R Sun, Z Hou, Y Zhang, B Jiang - Oncology Letters, 2022 - spandidos-publications.com
According to global cancer data, lung cancer was the leading cause of cancer‑related death
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …
An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy
Epithelial growth factor receptor (EGFR), a transmembrane receptor on the cell surface,
carries extracellular messages into the cell and alters the activity of the nucleus through …
carries extracellular messages into the cell and alters the activity of the nucleus through …
Role of protein phosphorylation in cell signaling, disease, and the intervention therapy
K Pang, W Wang, JX Qin, ZD Shi, L Hao, YY Ma… - MedComm, 2022 - Wiley Online Library
Protein phosphorylation is an important post‐transcriptional modification involving an
extremely wide range of intracellular signaling transduction pathways, making it an …
extremely wide range of intracellular signaling transduction pathways, making it an …
Multi‐target angiogenesis inhibitor combined with PD‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of EGFR‐TKI …
L Yu, Y Hu, J Xu, R Qiao, H Zhong… - … Journal of Cancer, 2023 - Wiley Online Library
Treatments for NSCLC patients with EGFR‐TKI resistance are limited. Given that
immunotherapy and antiangiogenic agents may have synergistic antitumor effects, we …
immunotherapy and antiangiogenic agents may have synergistic antitumor effects, we …
Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?
Introduction Epidermal growth factor receptor (EGFR) is frequently amplified, overexpressed,
and mutated in multiple cancers. In normal cell physiology, EGFR signaling controls cellular …
and mutated in multiple cancers. In normal cell physiology, EGFR signaling controls cellular …
The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer
Z Cheng, H Cui, Y Wang, J Yang, C Lin… - Oncology …, 2024 - spandidos-publications.com
Lung cancer is currently the second most common type of cancer with the second incidence
rate and the first mortality rate worldwide. Non-small cell lung cancer (NSCLC) accounts for …
rate and the first mortality rate worldwide. Non-small cell lung cancer (NSCLC) accounts for …